Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients' lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. Show more
Location: 188 East Blaine St., Suite 200, Washington, 98102, US | Website: www.alpineimmunesciences.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$64.97
Open
$64.97
Volume
2
Day Range
$64.97 - $64.97
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
4.65%
Institutional Own.
99.47%
Qtr Updated
06/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Acazicolcept (ALPN-101) Details Systemic lupus erythematosus | Phase 2 Data readout | |
Povetacicept (ALPN-303) Details Autoimmune disease, Autoimmune nephritis, Immune complex membranoproliferative glomerulonephritis, IgA nephropathy | Phase 2 Data readout | |
Povetacicept (ALPN-303) Details Autoimmune disease, Systemic lupus erythematosus | Phase 2 Initiation | |
Povetacicept (ALPN-303) Details Autoimmune disease, Primary immune thrombocytopenia | Phase 1b Update | |
Davoceticept (ALPN-202) (CD28 costimulator) Details Advanced malignancies | Failed Discontinued |